Update: Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Update: Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma

, MT Newswires - 4:29 AM ET 3/28/2025 default

04:29 AM EDT, 03/28/2025 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Portage Biotech ( PRTG ) shares were up nearly 109% in recent premarket activity Friday after the company reported overnight "encouraging" efficacy data in a murine mesothelioma model with PORT-7 given as a single agent or in combination with an anti-PD-1 antibody.

The data showed both single-agent activity and more than 90% inhibition of tumor growth when combined with an anti-PD1 antibody in a murine model of mesothelioma, the company said late Thursday.

"This is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor," Portage said, adding that it's preparing to start a first-in-human trial.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.